- Home
- FINS vs KMDA Comparison
FINS vs KMDA Comparison
Compare FINS & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINS | KMDA |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.2M | 460.3M |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | FINS | KMDA |
|---|---|---|
| Price | $12.70 | $7.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 33.7K | ★ 54.0K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.94 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.38 | $6.50 |
| 52 Week High | $13.55 | $9.35 |
Technical Indicators
Market Signals| Indicator | FINS | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 28.92 |
| Support Level | $12.47 | $6.87 |
| Resistance Level | $13.18 | $7.41 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 42.65 | 0.56 |
Price Performance
Historical ComparisonAbout FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term Trust is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.